Showing results (11-20 of 125) with videos related to
Sort By:
Pageof 13
Cancer Treatment Reviews|February 10, 2022
Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysisGuillermo Villacampa, Pablo Tolosa, Fernando Salvador, et al.European Journal of Cancer (Oxford, England : 1990)|February 5, 2005
Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapyRicardo Hitt, Eva Ciruelos, María L Amador, et al.Future Oncology (London, England)|August 13, 2020
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancerMiguel Martin, Jose A Garcia-Saenz, Luis Manso, et al.Expert Review of Anticancer Therapy|September 16, 2011
Implication of miRNA in the diagnosis and treatment of breast cancerCarlos A Castañeda, María Teresa Agullo-Ortuño, Juan Angel Fresno Vara, et al.Journal of Breast Cancer|January 4, 2020
Ribociclib-Related Stevens-Johnson Syndrome: Oncologic Awareness, Case Report, and Literature ReviewVictoria López-Gómez, Ramón Yarza, Héctor Muñoz-González, et al.Proteomics. Clinical Applications|February 26, 2013
Shotgun proteomics of archival triple-negative breast cancer samplesAngelo Gámez-Pozo, Nuria Ibarz Ferrer, Eva Ciruelos, et al.Oncotarget|July 16, 2019
Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approvalEva Ciruelos, Emilio Alba, Rafael López, et al.Breast (Edinburgh, Scotland)|June 4, 2021
The role of CDK4/6 inhibitors in early breast cancerMiguel Gil-Gil, Emilio Alba, Joaquín Gavilá, et al.Ecancermedicalscience|May 13, 2016
Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastasesKaterin Rojas Laimito, Angelo Gámez-Pozo, Juan Sepúlveda, et al.American Journal of Clinical Oncology|August 19, 2009
Reports of clinical benefit of plitidepsin (Aplidine), a new marine-derived anticancer agent, in patients with advanced medullary thyroid carcinomaChristophe Le Tourneau, Sandrine Faivre, Eva Ciruelos, et al.Pageof 13